Panacea Biotec Limited (PANACEABIO.BO)
INR 465.0
(2.69%)
INR 465.0
(2.69%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -309.7 Million INR | 46.43% |
| 2022 | -1.05 Billion INR | -97.32% |
| 2021 | -537.05 Million INR | -263.81% |
| 2020 | 327.85 Million INR | 183.44% |
| 2019 | 115.67 Million INR | 109.82% |
| 2018 | -1.17 Billion INR | -509.49% |
| 2017 | 287.57 Million INR | 150.7% |
| 2016 | -567.2 Million INR | -199.63% |
| 2015 | -189.3 Million INR | 80.96% |
| 2014 | -994.1 Million INR | 10.41% |
| 2013 | -1.1 Billion INR | 56.15% |
| 2012 | -2.53 Billion INR | 0.89% |
| 2011 | -2.55 Billion INR | -226.65% |
| 2010 | 2.01 Billion INR | 29.06% |
| 2009 | 1.56 Billion INR | 403.36% |
| 2008 | -514.9 Million INR | -125.36% |
| 2007 | 2.03 Billion INR | -11.52% |
| 2006 | 2.29 Billion INR | 102.54% |
| 2005 | 1.13 Billion INR | 115.18% |
| 2004 | 526.41 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -227.2 Million INR | -53.0% |
| 2023 Q3 | -35.8 Million INR | 72.18% |
| 2023 Q2 | -128.7 Million INR | 34.97% |
| 2023 Q1 | -197.9 Million INR | -30.37% |
| 2023 FY | -567.7 Million INR | 46.43% |
| 2023 Q4 | -148.5 Million INR | -314.8% |
| 2022 Q2 | -137.3 Million INR | 84.72% |
| 2022 FY | -1.05 Billion INR | -97.32% |
| 2022 Q4 | -151.8 Million INR | 17.09% |
| 2022 Q3 | -183.1 Million INR | -33.36% |
| 2022 Q1 | -898.6 Million INR | -117.37% |
| 2021 FY | -537.05 Million INR | -263.81% |
| 2021 Q3 | 13.1 Million INR | 126.84% |
| 2021 Q2 | -48.8 Million INR | 61.3% |
| 2021 Q1 | -126.1 Million INR | -18.52% |
| 2021 Q4 | -413.4 Million INR | -3255.73% |
| 2020 Q4 | -106.4 Million INR | -287.32% |
| 2020 FY | 327.85 Million INR | 183.44% |
| 2020 Q1 | 124.6 Million INR | -7.01% |
| 2020 Q2 | 287 Million INR | 130.34% |
| 2020 Q3 | 56.8 Million INR | -80.21% |
| 2019 Q4 | 133.99 Million INR | -54.44% |
| 2019 Q2 | -135.9 Million INR | -179.38% |
| 2019 FY | 115.67 Million INR | 109.82% |
| 2019 Q3 | 294.1 Million INR | 316.41% |
| 2019 Q1 | 171.2 Million INR | 141.5% |
| 2018 Q2 | -216.5 Million INR | 17.99% |
| 2018 FY | -1.17 Billion INR | -509.49% |
| 2018 Q4 | -412.52 Million INR | -56.32% |
| 2018 Q3 | -263.9 Million INR | -21.89% |
| 2018 Q1 | -264 Million INR | 0.0% |
| 2017 FY | 287.57 Million INR | 150.7% |
| 2016 FY | -567.2 Million INR | -199.63% |
| 2015 FY | -189.3 Million INR | 80.96% |
| 2014 FY | -994.1 Million INR | 10.41% |
| 2013 FY | -1.1 Billion INR | 56.15% |
| 2012 FY | -2.53 Billion INR | 0.89% |
| 2011 FY | -2.55 Billion INR | -226.65% |
| 2010 FY | 2.01 Billion INR | 29.06% |
| 2009 FY | 1.56 Billion INR | 403.36% |
| 2008 FY | -514.9 Million INR | -125.36% |
| 2007 FY | 2.03 Billion INR | -11.52% |
| 2006 FY | 2.29 Billion INR | 102.54% |
| 2005 FY | 1.13 Billion INR | 115.18% |
| 2004 FY | 526.41 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alfavision Overseas (India) Limited | 9.28 Million INR | 3436.206% |
| Biocon Limited | 50.83 Billion INR | 100.609% |
| Blue Jet Healthcare Limited | 3.37 Billion INR | 109.184% |
| Concord Biotech Limited | 6.26 Billion INR | 104.946% |
| Dishman Carbogen Amcis Limited | -13.9 Million INR | -2128.058% |
| FERMENTA BIOTECH LIMITED | 1.06 Billion INR | 129.0% |
| GENOMIC VALLEY BIOTECH LIMITED | 1.27 Million INR | 24375.916% |
| Lyka Labs Limited | 29.13 Million INR | 1163.165% |
| SAMSRITA LABS LIMITED | -1.49 Million INR | -20582.793% |
| Servoteach Industries Limited | -785.00 INR | -39452129.299% |
| SMS Lifesciences India Limited | 359.47 Million INR | 186.154% |
| Supriya Lifescience Limited | 1.57 Billion INR | 119.705% |
| Syngene International Limited | 14.02 Billion INR | 102.208% |
| TAKE Solutions Limited | -213.49 Million INR | -45.065% |
| Titan Biotech Limited | 315.89 Million INR | 198.038% |
| Transgene Biotek Limited | -7.08 Million INR | -4268.74% |
| Vanta Bioscience Limited | -31.83 Million INR | -872.737% |